*EPF407 09/02/2004
Text: World Must Intensify Push to Find an HIV Vaccine
(Vaccine research needs should not be sidelined in rush for treatment, expert says) (880)

The global community is making significant progress in scaling up treatment for HIV-infected persons in the developing world, but in doing so, must not falter in the pursuit of a vaccine to prevent infection, said the leader of the International AIDS Vaccine Initiative (IAVI) September 2.

Speaking at a conference in Switzerland, Dr. Seth Berkley said, "The global response to AIDS must include both compassion for those who are infected and a heightened commitment to protect those who are not."

Development of a vaccine has been a greater challenge than medical science imagined when pursuit of this goal began almost 20 years ago. The HIV virus constantly mutates and avoids detection, and although researchers have learned a great deal about how the virus is able to do that, much remains unknown.

Berkley called on the international community to develop greater resources in pursuit of a vaccine, and for greater cooperation among those in the vaccine field to speed the development of an effective vaccine. More than 30 AIDS vaccine candidates are undergoing trials, but those drugs are regarded as preliminary attempts rather than near-successes.

The United States is a partner in supporting the IAVI along with other major private and governmental donors, including the European Union and the Bill and Melinda Gates Foundation.

Following is the text from the IAVI:

(begin text)

International AIDS Vaccine Initiative

Global response to AIDS must include a preventive vaccine

GENEVA, September 2, 2004-Leaders of the International AIDS Vaccine Initiative (IAVI) stressed today that as the world commits more resources to treat people infected with HIV, it must also intensify efforts to develop a vaccine to prevent new infections and stop the continuing spread of the virus. Dr. Seth Berkley, MD, President and CEO of IAVI, and Dr. Wayne Koff, IAVI's Senior Vice President and Chief of Vaccine Research, briefed reporters at the United Nations in Geneva, following a major conference in Lausanne where scientists discussed preliminary data on candidate vaccines entering clinical trials.

Treatment programs, such as the World Health Organization's 3x5 Initiative, are helping people with HIV live longer, restoring hope to communities decimated by AIDS deaths. However, treatment does not stop new infections, which are occurring at the rate of 14,000 each day. Some of the most alarming trends in new infections are in Asia and Eastern Europe, and among young women.

"The global response to AIDS must include both compassion for those who are infected and a heightened commitment to protect those who are not," Dr. Berkley said.

HIV was identified more than 20 years ago. It is only in recent years that significant progress has begun to be made toward a vaccine. In particular, scientists have learned a great deal about the structure of the virus, how infection occurs and how the immune system tries but fails to defend itself. This dynamic is at the heart of the science of how a vaccine needs to work.

Yet the questions that have been answered are outnumbered by those that have not. For most vaccines for other diseases, scientists have been guided by studying people who became infected and then recovered; in the case of AIDS, there is no one known to have recovered from infection. In addition, HIV is a moving target, constantly mutating its shape to evade detection.

"Given what we know about HIV today, we are advancing promising candidates into development and clinical trials. At the same time, basic research questions still must be solved," Dr. Koff said.

Currently, more than 30 AIDS vaccine candidates are in clinical trials in 19 countries, including five IAVI-sponsored candidates in eight countries. At this stage, experts view the current crop of candidates as a first generation attempt. They expect that an effective vaccine is likely to be developed after more is understood about HIV and the immune system, and new generations of candidates are developed and tested.

IAVI is calling on the vaccine field-including pharmaceutical and biotechnology companies, and public sector research agencies-to work more aggressively and cooperatively to advance progress. This will require substantial new funding; of the US$70 billion spent each year globally on health product R&D, less than 1% is dedicated to an AIDS vaccine.

Recognizing the toll that AIDS has already exacted, and the magnitude of what is yet to come, the world must push a preventive vaccine to the top of international health and humanitarian agendas.

Contact: Bodine Williams, +1 646 239 1670

About IAVI: IAVI (www.iavi.org) is a global not-for-profit organization working to accelerate the development of a vaccine to prevent HIV infection and AIDS. Founded in 1996 and operational in 23 countries, IAVI and its network of collaborators research and develop vaccine candidates. IAVI also works to assure that a vaccine will be accessible to everyone who needs it. IAVI's major financial supporters include the Bill & Melinda Gates Foundation; the Rockefeller, Sloan and Starr foundations; the World Bank; BD (Becton, Dickinson & Co.); the European Union; and the governments of Canada, Denmark, Ireland, the Netherlands, Norway, Sweden, the United Kingdom and the United States.

(end text)

(Distributed by the Bureau of International Information Programs, U.S. Department of State. Web site: http://usinfo.state.gov)

Return to Public File Main Page

Return to Public Table of Contents